Company plans to create a new healthcare business as part of its transformation and growth strategy
Teijin Pharma, part of Teijin Group’s medical and pharmaceutical business, has opened a Technology Integrated Pharmaceutics Center to leverage the group’s material and pharmaceutical development resources. The new two-storey building will be equipped with good manufacturing practice (GMP) zones, manufacturing and testing equipment, and unique R&D facilities for pharmaceutical-material integration.
The facility, measuring 2300m2, will be located in the pharmaceutical product research laboratories of Teijin’s Iwakuni factory in western Japan at a cost of approximately US$16.3m.
Teijin is aiming to create a new healthcare business by overlapping the group’s materials and healthcare domains as part of its transformation and growth strategy. The Technology Integrated Pharmaceutics Center will offer consolidated R&D functions and facilitate the manufacture of investigational drugs and the development of mass production processes for KTF-374, a promising fibrin sheet offering high-performance haemostatic and tissue-sealing properties for surgical operations.